What is SymCel?
SymCel specializes in rapid sterility testing and microbial detection systems, utilizing biocalorimetry to measure metabolic heat from living organisms. Their product suite includes calScreener+ and calScreener, designed for applications in clinical research, food microbiology, and environmental testing. The company aims to improve manufacturing efficiency and patient access by reducing sterility testing times to under three days. Their intended clients include developers and clinical labs in the fields of cell and gene therapies, probiotics, and microbiome research. This technological advancement offers a substantial improvement over traditional testing methodologies, promising faster product release cycles and enhanced safety.
How much funding has SymCel raised?
SymCel has raised a total of $4.2M across 1 funding round:
Grant
$4.2M
Grant (2017): $4.2M, investors not publicly disclosed
What's next for SymCel?
With a substantial enterprise-level funding context and a recent strategic investment, SymCel is poised for significant expansion and product development. The company's focus on accelerating sterility testing to under three days addresses a critical bottleneck in industries such as cell and gene therapies, probiotics, and microbiome research. This strategic backing will likely fuel further research and development, enhance manufacturing capabilities, and broaden market penetration. SymCel's innovative biocalorimetry approach is set to redefine microbial detection standards, offering greater efficiency and reliability to clinical labs and product developers.
See full SymCel company page
